Stock Analysis
PROCEPT BioRobotics Corporation (PRCT) Stock Analysis
PROCEPT BioRobotics Corporation (PRCT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
PROCEPT BioRobotics Corporation (PRCT) currently has an AIQ Score of 49/100, indicating a bearish setup. Momentum is the strongest factor at 60/100. Value is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
PRCT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $25.18 |
| AIQ Score | 49/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $1.36B |
| P/E Ratio (TTM) | -11.77 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.46 |
| Revenue (Q3 FY2026) | $98.29M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.01 |
| Volume | 2.05M |
| 52-week range | $16.67-$38.11 |
| RSI 14 | 69.03 |
| 50-Day SMA | $19.52 |
| 200-Day SMA | $22.91 |
| Analyst Price Target | $30.00 |
| Next Earnings | Feb 24, 2027 |
PRCTPROCEPT BioRobotics Corporation
Healthcare / Medical - Devices
Low Priority
In Line With Peers
Latest quote
- Momentum60
- Value38
- Quality45
- Risk resilience45
- Sentiment—
PRCT Stock Analysis Summary
PROCEPT BioRobotics Corporation (PRCT) currently has an AIQ Score of 49/100, indicating a bearish setup. Momentum is the strongest factor at 60/100. Value is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, PRCT has AIQ Score of 49/100 with Momentum base of 60/100 and fading Value at 38/100. Wait for component alignment before adding exposure.
Momentum (60/100) leads while Value (38/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 5.89% stock move · PRCT classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is PRCT Bullish or Bearish Right Now?
PRCT currently has a bearish overall setup. Momentum is the strongest factor at 60/100, while Value is weakest at 38/100. The current evidence suggests a bearish setup.
- - Price is +21.95% above its 50-day SMA.
- - Analyst target implies +19.14% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (36 vs 7).
- - Value is the current constraint at 38/100.
- - Risk Resilience is weak at 45/100.
Current Consensus
PRCT's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 3 neutral, and 7 sell votes. PRCT's 14-day RSI is 69.03, which places the stock in a constructive momentum range. PRCT's beta is 1.01, indicating market sensitivity broadly in line with the market.
What Changed in PRCT?
The largest recent change in PRCT is Momentum moving up by 8.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the PRCT Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
PRCT Decision Framework
Public evidence layers, setup checks, and risk context for PROCEPT BioRobotics Corporation.
PROCEPT BioRobotics Corporation (PRCT) Stock Analysis
PROCEPT BioRobotics Corporation has an AIQ Score of 49/100 in a Bearish regime. Momentum is strongest at 60/100. Beta is 1.01, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | PRCT is in a Bearish AIQ regime with score 49/100. |
| Signal Conflict | The primary conflict is that momentum leads at 60/100 while value lags at 38/100. |
| Factor Evidence | Momentum 60/100 · Value 38/100 · Quality 45/100 · Risk 45/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 60/100.
Momentum is 60/100 and RSI (14) is 69.0.
PRCT is in a Bearish regime at 49/100.
Risk factor is 45/100 with beta 1.01 and annual volatility 65.89%.
Current conflict: momentum leads at 60/100 while value lags at 38/100.
PRCT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
PRCT Fundamentals
PRCT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
PRCT Technical Analysis
PRCT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
PRCT Stock Catalysts
Track PRCT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
PRCT Dividend Analysis
PRCT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
PRCT Financial Data
PRCT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
PRCT Risk Analysis
PRCT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
PRCT Stock News
PRCT stock news, market tone, recent headlines, and catalyst context.
PRCT vs Medical - Devices Peers
Current peer cohort: PRCT · SNN · TNDM · UFPT · ATEC. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| PRCT Current stock | 49/100 | 38/100 | 60/100 | 45/100 | -0.11 | 65.89% | Current |
| SNN Smith & Nephew plc | 70/100 | 79/100 | 60/100 | 75/100 | -0.2 | 27.30% | PRCT vs SNN |
| TNDM Tandem Diabetes Care, Inc. | 55/100 | 64/100 | 59/100 | 38/100 | 0.49 | 75.74% | PRCT vs TNDM |
| UFPT UFP Technologies, Inc. | 68/100 | 61/100 | 81/100 | 56/100 | 0.69 | 50.83% | PRCT vs UFPT |
| ATEC Alphatec Holdings, Inc. | 48/100 | 61/100 | 47/100 | 28/100 | -0.94 | 78.93% | PRCT vs ATEC |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for PRCT: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 19, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching PRCT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for PRCT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
PRCT Stock FAQ
What is PRCT stock price today?
PROCEPT BioRobotics Corporation's current stock price is $25.18. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is PRCT bullish or bearish right now?
PRCT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is PRCT's market cap?
PRCT's market cap is $1.36B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is PRCT's current P/E ratio?
PRCT's current P/E ratio is -11.77 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is PRCT's RSI?
PRCT's 14-day RSI is 69.03 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is PRCT above its 50-day and 200-day moving averages?
PRCT is 21.95% from its 50-day SMA and 3.90% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is PRCT's next earnings date?
PRCT's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does PRCT pay a dividend?
PRCT's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.